Madrigal Pharmaceuticals (MDGL) Net Equity Issued and Repurchased (2010 - 2025)
Madrigal Pharmaceuticals (MDGL) posted quarterly Net Equity Issued and Repurchased of $9.9 million for Q4 2025, up 43313.04% year-over-year from N/an in Q4 2024, and down 43.96% quarter-over-quarter from $17.7 million in Q3 2025.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Net Equity Issued and Repurchased (2010 - 2025) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Net Equity Issued and Repurchased for 12 consecutive years, with $9.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased rose 43313.04% year-over-year to $9.9 million; the TTM figure through Dec 2025 stood at $38.1 million (down 90.43% YoY), while the FY2025 annual figure was $38.1 million, down 90.43% from the prior year.
- Net Equity Issued and Repurchased slipped to $9.9 million in Q4 2025 per MDGL's latest filing, from $17.7 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $311.6 million in Q1 2024 and bottomed at -$23000.0 in Q4 2024.
- Historically, Net Equity Issued and Repurchased has averaged $64.2 million across 3 years, with a median of $9.9 million in 2025.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased plunged 100.01% — and 2025, when it soared 43313.04%.
- Madrigal Pharmaceuticals' Net Equity Issued and Repurchased stood at $244.2 million in 2023, then slumped by 100.01% to -$23000.0 in 2024, then jumped by 43313.04% to $9.9 million in 2025.
- Business Quant data shows MDGL's Net Equity Issued and Repurchased at $9.9 million in Q4 2025, $17.7 million in Q3 2025, and $1.7 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 14.96 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 9.94 Mn |
| Sep 30, 2025 | 17.74 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 8.64 Mn |
| Dec 31, 2024 | -23,000.00 |
| Jun 30, 2024 | 85.95 Mn |
| Mar 31, 2024 | 311.56 Mn |
| Dec 31, 2023 | 244.21 Mn |
| Sep 30, 2023 | 1.93 Mn |
| Jun 30, 2023 | 6.25 Mn |
| Mar 31, 2023 | 17.90 Mn |
| Jun 30, 2018 | 311.80 Mn |
| Dec 31, 2017 | 135.70 Mn |
| Sep 30, 2017 | -21,000.00 |
| Jun 30, 2017 | 34.90 Mn |
| Mar 31, 2017 | 3.40 Mn |
| Dec 31, 2016 | 6.00 Mn |
| Dec 31, 2015 | -36.94 Mn |
| Sep 30, 2015 | 7.83 Mn |
| Dec 31, 2014 | 1,000.00 |